Skip to main content
TipRanks
Go Ultimate75% OFF

Compare iX Biopharma Ltd. (42C) vs. Competitors

26 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
SG:42CiX Biopharma Ltd.SGD 0.46SGD 498.68M-54.82250.00%Strong BuyUnlock the SG:42C analyst price target with TipRanks PremiumSG:42CUnlock the SG:42C top-analyst price target with TipRanks Premium
SG:P8ACordlife GroupSGD 0.09SGD 23.23M-2.06-46.78%―Unlock the SG:P8A analyst price target with TipRanks PremiumSG:42C vs SG:P8AUnlock the SG:P8A top-analyst price target with TipRanks Premium
SG:1J5Hyphens Pharma International Ltd.SGD 0.35SGD 108.22M12.680.00%Moderate BuyUnlock the SG:1J5 analyst price target with TipRanks PremiumSG:42C vs SG:1J5Unlock the SG:1J5 top-analyst price target with TipRanks Premium
SG:546Medtecs International Corporation Ltd.SGD 0.10SGD 51.91M-8.96-22.76%―Unlock the SG:546 analyst price target with TipRanks PremiumSG:42C vs SG:546Unlock the SG:546 top-analyst price target with TipRanks Premium
SG:8YYBiolidics Ltd.SGD 0.02SGD 36.40M-11.05-4.55%―Unlock the SG:8YY analyst price target with TipRanks PremiumSG:42C vs SG:8YYUnlock the SG:8YY top-analyst price target with TipRanks Premium
SG:9G2Singapore Institute of Advanced Medicine Holdings Ltd.SGD 0.03SGD 44.83M-1.15-38.10%―Unlock the SG:9G2 analyst price target with TipRanks PremiumSG:42C vs SG:9G2Unlock the SG:9G2 top-analyst price target with TipRanks Premium

Performance Comparison

-100%0%100%200%300%400%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
SG:42CiX Biopharma Ltd.0.460.33261.11%
SG:P8ACordlife Group0.09-0.08-46.78%
SG:1J5Hyphens Pharma International Ltd.0.350.026.06%
SG:546Medtecs International Corporation Ltd.0.10-0.03-22.13%
SG:8YYBiolidics Ltd.0.02-0.00-4.55%
SG:9G2Singapore Institute of Advanced Medicine Holdings Ltd.0.03-0.01-31.58%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts